(CRSP) Crispr Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 4.639m USD | Total Return: 34.2% in 12m
Avg Turnover: 82.8M
Qual. Beats: 0
Rev. Trend: -87.6%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -12.7 is critical
Altman Z'' -0.74 < 1.0 - financial distress zone
Choppy
Tailwinds
Confidence
CRISPR Therapeutics AG is a Swiss biotechnology firm specializing in gene editing through the CRISPR/Cas9 platform. The company develops therapies by precisely altering genomic DNA sequences to treat serious conditions, including hemoglobinopathies, autoimmune diseases, and oncology. Its primary product, CASGEVY, is an ex vivo cell therapy developed in partnership with Vertex Pharmaceuticals for sickle cell disease and beta-thalassemia.
The company operates within the high-growth genomic medicine sector, which relies on a platform-based business model where a single core technology can be applied across multiple therapeutic areas. Unlike traditional pharmaceuticals, gene editing often targets the underlying genetic cause of a disease rather than managing symptoms. Investors can find additional data and comparative insights on ValueRay to further evaluate this sector.
The current pipeline includes CAR T cell programs such as CTX112 and CTX131, alongside in vivo candidates CTX310 and CTX320 designed to address cardiovascular disease. These programs utilize both autologous and allogeneic approaches to modify immune cells or disrupt specific protein targets within the body. The company maintains a strategic focus on scaling its proprietary platform through internal development and industry collaborations.
- Commercial uptake of CASGEVY drives initial revenue and market validation
- Expansion of oncology pipeline into autoimmune indications increases addressable market
- Progress of in vivo cardiovascular programs reduces long-term platform risk
- Partnership milestones and cost-sharing with Vertex Pharmaceuticals influence cash runway
- Regulatory approval timelines for next-generation CAR T therapies impact valuation
| Net Income: -568.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA -4.74 > 1.0 |
| NWC/Revenue: 56.4k% < 20% (prev 4.73k%; Δ 51.6k% < -1%) |
| CFO/TA -0.15 > 3% & CFO -400.0m > Net Income -568.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (96.1m) vs 12m ago 11.77% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.17% > 50% (prev 1.71%; Δ -1.54% > 0%) |
| Interest Coverage Ratio: -12.70 > 6 (EBITDA TTM -504.9m / Interest Expense TTM 41.3m) |
| A: 0.85 (Total Current Assets 2.45b - Total Current Liabilities 136.3m) / Total Assets 2.73b |
| B: -0.76 (Retained Earnings -2.07b / Total Assets 2.73b) |
| C: -0.21 (EBIT TTM -523.9m / Avg Total Assets 2.45b) |
| D: -2.27 (Book Value of Equity -2.07b / Total Liabilities 911.3m) |
| Altman-Z'' = -0.74 = B |
As of May 24, 2026, the stock is trading at USD 49.90 with a total of 1,427,703 shares traded.
Over the past week, the price has changed by +4.03%,
over one month by -10.74%,
over three months by -6.71% and
over the past year by +34.19%.
Crispr Therapeutics has received a consensus analysts rating of 3.96. Therefore, it is recommended to buy CRSP.
- StrongBuy: 12
- Buy: 5
- Hold: 10
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 82.8 | 66% |
P/S = 1130.6816
P/B = 2.5806
P/EG = -0.2142
Revenue TTM = 4.10m USD
EBIT TTM = -523.9m USD
EBITDA TTM = -504.9m USD
Long Term Debt = 585.5m USD (from longTermDebt, last quarter)
Short Term Debt = 18.6m USD (from shortTermDebt, last quarter)
Debt = 989.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 202.2m
Net Debt = -1.45b USD (calculated: Debt 989.8m - CCE 2.44b)
Enterprise Value = 3.19b USD (4.64b + Debt 989.8m - CCE 2.44b)
Interest Coverage Ratio = -12.70 (Ebit TTM -523.9m / Interest Expense TTM 41.3m)
EV/FCF = -6.61x (Enterprise Value 3.19b / FCF TTM -482.1m)
FCF Yield = -15.13% (FCF TTM -482.1m / Enterprise Value 3.19b)
FCF Margin = -11.7k% (FCF TTM -482.1m / Revenue TTM 4.10m)
Net Margin = -13.9k% (Net Income TTM -568.5m / Revenue TTM 4.10m)
Gross Margin = unknown ((Revenue TTM 4.10m - Cost of Revenue TTM 224.1m) / Revenue TTM)
Tobins Q-Ratio = 1.17 (Enterprise Value 3.19b / Total Assets 2.73b)
Interest Expense / Debt = 4.17% (Interest Expense 41.3m / Debt 989.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -413.9m (EBIT -523.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.33 (Total Current Assets 2.45b / Total Current Liabilities 149.9m)
Debt / Equity = 0.55 (Debt 989.8m / totalStockholderEquity, last quarter 1.81b)
Debt / EBITDA = 2.88 (negative EBITDA) (Net Debt -1.45b / EBITDA -504.9m)
Debt / FCF = 3.01 (negative FCF - burning cash) (Net Debt -1.45b / FCF TTM -482.1m)
Total Stockholder Equity = 1.84b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.24% (Net Income -568.5m / Total Assets 2.73b)
RoE = -14.54% (Net Income TTM -568.5m / Total Stockholder Equity 3.91b)
RoCE = -11.65% (EBIT -523.9m / Capital Employed (Equity 3.91b + L.T.Debt 585.5m))
RoIC = -16.85% (negative operating profit) (NOPAT -413.9m / Invested Capital 2.46b)
WACC = 10.73% (E(4.64b)/V(5.63b) * Re(12.32%) + D(989.8m)/V(5.63b) * Rd(4.17%) * (1-Tc(0.21)))
Discount Rate = 12.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 7.68%
[DCF] Fair Price = unknown (Cash Flow -482.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.53 | # QB: 0
Revenue Correlation: -87.63 | Revenue CAGR: -78.10% | SUE: -0.22 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.18 | Chg30d=+4.57% | Revisions=+24% | Analysts=19
EPS next Quarter (2026-09-30): EPS=-1.18 | Chg30d=+1.10% | Revisions=+14% | Analysts=19
EPS current Year (2026-12-31): EPS=-4.79 | Chg30d=+3.09% | Revisions=+4% | GrowthEPS=+26.0% | GrowthRev=+1175.8%
EPS next Year (2027-12-31): EPS=-4.00 | Chg30d=+4.50% | Revisions=+16% | GrowthEPS=+16.5% | GrowthRev=+234.8%
[Analyst] Revisions Ratio: +24%